TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04250259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months
Study: NCT01807741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02062346
Drug: BQ123/788
Approvals — FDA: no, EMA: no, PMDA: no
Description: or BQ123/788 (mixed ETA/B antagonists)
Study: NCT02062346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of saline
Study: NCT00814736
Drug: UK369,003
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, once a day
Study: NCT04315961
Drug: Blinded drug dose conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules will contain commonly prescribed or over-the-counter drugs or placebo. Capsules in this study may contain sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, or antihistamines which must remain blinded for the purposes of this study.
Study: NCT01548326
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one Placebo tablet orally per day for 10 days
Study: NCT01485198
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (750mg orally TID) administration
Study: NCT01908699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
Study: NCT01084551
Drug: SPM 962
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks
Study: NCT01084551
Drug: SPM 962
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks
Study: NCT01084551
Drug: Placebo of SPM 962
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a daily transdermal administration for 13 weeks
Study: NCT00836901
Drug: Augmentin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg-57 mg chewable tablet
Study: NCT04250207
Drug: K-321 Solution
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-321 solution drops
Study: NCT04250207
Drug: Placebo Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution drops for K-321
Study: NCT03945253
Drug: ASP8374
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT03464461
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV drug
Study: NCT03263390
Drug: Anti Obesity Drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response to FDA approved anti obesity medications
Study: NCT01687595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: phosphate buffered saline
Study: NCT02524899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in placebo arm will have matching schedule as active arm.
Study: NCT00706537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as two tablets once daily for three weeks
Study: NCT03422887
Drug: Nalbuphine and Flurbiprofen Axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine and Flurbiprofen Axetil administration during surgery
Study: NCT00773591
Drug: NT 201, a Botulinum neurotoxin type A, free of complexing proteins
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.
Study: NCT03633487
Drug: Mucinex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucinex® 1200 mg ER Bi-Layer tablet
Study: NCT00667979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT03480750
Drug: pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated liposomal doxorubicin 40mg/m2 IV D1
Study: NCT03419624
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet once daily
Study: NCT03419624
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection once weekly
Study: NCT00236795
Drug: norelgestromin + ethinyl estradiol; triphasil.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00549211
Drug: GSK557296
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02397473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00019760
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01922895
Drug: Placebo for Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule manufactured without active ingredients.
Study: NCT01916226
Drug: FPNS
Normalized name: Fluticasone Propionate and Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
Study: NCT01916226
Drug: FPNS Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
Study: NCT01170754
Drug: PEG-3350 and Gatorade
Approvals — FDA: no, EMA: no, PMDA: no
Description: 255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation.
Study: NCT01170754
Drug: Golytely 4 liters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golytely 4 liters
Study: NCT04086290
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
Study: NCT00020007
Drug: isolated perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00421967
Drug: Ropivacaine, Ketorolac, adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration: 150 ml Ropivacaine 2mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml Adrenaline 1 mg/ml Intraarticular infusion: 4 ml/h 384 mg Ropivacaine 60 mg Ketorolac
Study: NCT00421967
Drug: Ropivacaine Ketorolac
Normalized name: CLONIDINE/KETOROLAC/ROPIVACAINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion: 4 ml/h 384 mg Ropivacaine I.V. Ketorolac 90 mg
Study: NCT02420314
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Administered intravenously (IV)~* 75g per infusion~* Two infusions per week~* 1 cycle is 3 weeks~* given up to 4 cycles~* may be given while chemotherapy if delayed due to low counts
Study: NCT02062684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02594579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
Study: NCT02915601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03019653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
Study: NCT01848457
Drug: High-dose methotrexate infusion duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
Study: NCT02770365
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03620981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 1 tablet /day Once daily for 10 weeks
Study: NCT03105765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.
Study: NCT00257933
Drug: Prednisolone high dose
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg/kg/day orally divided every 6 hours (maximum 30 mg per dose)
Study: NCT00257933
Drug: Prednisolone lower dose
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg/kg/day orally divided q 12 (maximum 30mg/dose) alternating with placebo
Study: NCT03947385
Drug: IDE196
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDE196 dosed orally, twice daily for each 28-day cycle
Study: NCT01878474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose in Caucasian men
Study: NCT01878474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-effect in Caucasian men
Study: NCT01878474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender-effect in Caucasian women
Study: NCT01878474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose in Japanese men
Study: NCT03228043
Drug: CAPEOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPEOX adjuvant chemotherapy for resectable colorectal
Study: NCT01097681
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03973489
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.
Study: NCT01887600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
Study: NCT03625648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02006836
Drug: met or diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: In diabetic group, 20 diabetic patients were included for GI measurement , 18 of whom were on metformin treatment. Only 2 patients were on diet control due to the early stage of this disease.
Study: NCT02797548
Drug: Aspirin only
Normalized name: Aspirin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin only during surgery
Study: NCT02797548
Drug: No antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet therapy will be during surgery
Study: NCT01610401
Drug: Pretreatment with metformin in combination of infusion of caffeine.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement
Study: NCT01610401
Drug: No pretreatment with metformin in combination with infusion of caffeine
Normalized name: acetaminophen / butalbital / caffeine / codeine Oral Capsule [Fioricet with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).
Study: NCT00107614
Drug: DT PACE + Rituxan
Approvals — FDA: no, EMA: no, PMDA: no
Description: INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with \< 50% response to induction) OR MEL-DT PACE (Patients with \> 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
Study: NCT01117662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous application of placebo (NaCl 0,9 %) matching active treatment
Study: NCT03638180
Drug: BLU-5937
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLU-5937 oral tablet
Study: NCT03638180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to BLU-5937
Study: NCT04109482
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 300 - 500 mg/m2/day IV (3 days) on days -5, -4, and -3
Study: NCT04505787
Drug: Esflurbiprofen hydrogel patch 165 mg (EFHP)
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patch application with PK blood sampling
Study: NCT04505787
Drug: Froben 100 mg comprimidos revestidos
Normalized name: flurbiprofen 100 MG [Froben]
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet administration with PK blood sampling
Study: NCT02584738
Drug: Nebulized Magnesium Sulfate
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours.
Study: NCT02584738
Drug: Nebulized isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours.
Study: NCT02584738
Drug: Methylprednisolone or Prednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
Study: NCT03362632
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observation study, no specific antibiotics will be indicated during treatment.
Study: NCT01073709
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00267046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 3 days prior to chemotherapy
Study: NCT00615160
Drug: PTK787/ZK 222584
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
Study: NCT02944045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline serum
Study: NCT00839930
Drug: Pletal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 50 mg, single-dose tablet
Study: NCT00859885
Drug: Antithrombotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiplatelets, anticoagulants
Study: NCT02386072
Drug: antimuscarinic medication
Normalized name: ANTIMUSCARINICS/ANTISPASMODICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00693108
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01592747
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, oral administration.
Study: NCT02957903
Drug: Isotonic Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
Study: NCT00176826
Drug: Myeloablative conditioning regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
Study: NCT00770796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01982747
Drug: MGN-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01982747
Drug: Placebo-MGN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01258699
Drug: Thiocacid HR Tab 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg for 1 day
Study: NCT03410771
Drug: Monitor antibiotic exposure (PK profile)
Approvals — FDA: no, EMA: no, PMDA: no
Description: several plasma samples to measure drug exposure
Study: NCT02088411
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02134808
Drug: Creatine
Normalized name: Creatine
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine is a nutritional supplement.
Study: NCT02134808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
Study: NCT01475825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vehicle for subcutaneous injection.
Study: NCT04157738
Drug: Rapid-Acting Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)
Study: NCT04157738
Drug: Long acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)
Study: NCT00001482
Drug: Gabapentin (Neurontin® (Registered Trademark))
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02096926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02096926
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg PO
Study: NCT02934217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single intravenous bolus injection of Placebo
Study: NCT01347086
Drug: Matching placebo (low dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of matching placebo
Study: NCT01347086
Drug: Matching placebo (medium dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching placebo
Study: NCT01347086
Drug: Matching placebo (high dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching placebo
Study: NCT01364662
Drug: SPN-810
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally
Study: NCT01546987
Drug: Anti-androgen
Normalized name: Anti-androgens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starts at same time as GnRH agonist, ends at end of radiation therapy. Either flutamide (orally 250 mg three times a day) or bicalutamide (orally 50 mg once a day).
Study: NCT01364662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally
Study: NCT02197065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02264821
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo in spinal anaesthesia and in wound infiltration
Study: NCT04937621
Drug: Treatment data collect
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline treatment data as well as follow-up treatment data are collected
Study: NCT02067156
Drug: G-202
Normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
Study: NCT01704989
Drug: Prostagladin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be initiated with latanoprost 0.005%. At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (\>35 mmHg) or advanced damage at presentation.
Study: NCT04424251
Drug: Experimental: stage I：HSK21542 0.4 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
Study: NCT04424251
Drug: Experimental: stage I：HSK21542 1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
Study: NCT04424251
Drug: Experimental: stage I：HSK21542 0.5μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Study: NCT04424251
Drug: Experimental: stage I：HSK21542 1μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Study: NCT04424251
Drug: Experimental: stage II：HSK21542 0.5μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Study: NCT04424251
Drug: Experimental: stage II：HSK21542 1μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Study: NCT04424251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Study: NCT03760081
Drug: ASP1650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received ASP1650 dose level 1 or dose level 2 as intravenous infusion, Q2W starting on C1D1 for up to a maximum of 12 cycles or until study discontinuation criterion was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.